Latest Articles

Publication Date
The inhibition of deep peritoneal endometriosis by Andrographolide through macrophage M1 activity in an endometriosis mice model.

This study aims to demonstrate that Andrographolide, an herbal immunostimulant, can influence M1 macrophages to inhibit inflammation, including the growth of endometriosis caused by inflammation. This study evaluates the effects …

Published: Feb. 27, 2026, midnight
Digital patient decision aids for endometriosis management: a scoping review protocol.

Endometriosis is a chronic, oestrogen-dependent condition with a wide range of symptoms and comorbidities that significantly affect physical, emotional and psychological well-being, as well as quality of life. Women with …

Published: Feb. 24, 2026, midnight
Primary dysmenorrhea in adolescents.

Dysmenorrhea is among the most common gynecological complaints in adolescents. Its diagnosis depends on the exclusion of other underlying pathologies, with the patient's history playing a crucial role. Initial therapy …

Published: Feb. 24, 2026, midnight
Fertility preservation in women with endometriosis: How, when, and for whom?

Fertility preservation options, including cryopreservation of oocytes, embryos, and ovarian tissue, were initially focused on women undergoing gonadotoxic chemotherapy for oncologic treatment. The indications have expanded to include nonmalignant conditions …

Published: Feb. 20, 2026, midnight
Adherence, Acceptability, and Sexual Health Outcomes of the Odeya App-Based Intervention for Sexual Distress in Women With Endometriosis: Randomized Controlled Mixed Methods Trial.

Evidence-based interventions effectively treat sexual dysfunctions. Up to 13.5% of women with gynecological conditions are affected, yet access to therapy is limited. Self-guided digital interventions may offer scalable, accessible first-line …

Published: Feb. 19, 2026, midnight
Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair.

Endometriosis is a chronic, hormone-dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, …

Published: Feb. 18, 2026, midnight
Precision-based solutions for endometriosis: Integrating immunomics and drug repositioning strategies.

Endometriosis (EMs) is an estrogen-dependent, chronic inflammatory disorder characterized by immune microenvironment dysregulation, a critical factor in its pathogenesis. Despite existing therapies, limitations persist, highlighting the urgent need for innovative …

Published: Feb. 16, 2026, midnight
Differences in response to dienogest therapy among different phenotypes of endometriosis: A single-center retrospective cohort analysis.

This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep …

Published: Feb. 15, 2026, midnight
Associations of baseline characteristics, patient-reported outcomes, and satisfaction with pain therapy with the patient's global impression of change: a prospective cohort study.

Patient-reported outcome measures (PROMs) are key elements of assessing the efficacy of perioperative pain management. Here, we aimed to capture the association of 10 individually reported aspects of patient's specific …

Published: Feb. 13, 2026, midnight
2-Deoxyglucose dendrimer-enabled niclosamide delivery to FRβ-expressing macrophages alleviates endometriosis progression and associated hyperalgesia.

Endometriosis is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, non-hormonal therapies is urgently needed. We …

Published: Feb. 12, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!